Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Nov 26, 2025
- Accession no.
- 0001628280-25-054126
- Filed
- Nov 26, 2025
- Trade date
- Nov 25, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $204.9K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 25, 2025 | Common Stock | SSaleDisposed | −5,115 | $40.05F2 | −$204,855.75 | 45,822 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $40.000 to $40.165, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.